PHARMACEUTICAL CO-CRYSTAL: AN EMERGING APPROACH TO IMPROVE PHYSICAL PROPERTY

Pharmaceutical co-crystals are nonionic supramolecular complexes and can be used to altered physical property issues such as solubility, stability and bioavailability in pharmaceutical development without affecting chemical composition of API. co-crystal comprising of API and desired stoichiometric acceptable co-crystal that can be made by various types of interaction like hydrogen bounding, pi-stacking and Vander wall forces. Pharmaceutical co-crystal is more thermodynamically stable than crystal form of drugs. The recent advancement in the co-crystal development arises the possibility to produce material by designing with an improved physical property.co-crystal not only provide a technique for improvement of physiochemical property but also provide opportunity to the researchers of pharmaceutical companies regarding intellectual property.co-crystal approach especially used to enhance the specific properties of pharmaceutical solids such as dissolution rate of poorly water soluble API and the physical stability of moisture liable APIs. Cocrystalization property creates opportunity for polymorphs, hydrate and also for salt selection. The various factors which will affect co-crystal stability will be taken in consideration and can be managed with the help of crystal engineering and thermodynamically stable product only accepted. Phase transformation during processing affect the mechanism of conversion of crystalline drugs to co-crystal.